Therapy and prophylaxis in newborn patients
DOI:
https://doi.org/10.7175/rhc.v4i1S.858Keywords:
Fungal infections, Prophylaxis, Fluconazole, Micafungin, Neonatal use, ProbioticsAbstract
Fluconazole is the most used drug for antifungal prophylaxis in neonatal population. Despite its effectiveness, sometimes fungal infections occur also in newborn patients undergoing fluconazole prophylaxis: this is mainly due both to biofilm formation in patients who carry a central venous catheter (CVC), a common condition among premature babies, and to the occurrence of an infection by a Candida subspecies with intrinsic resistance to fluconazole (e.g.: C. glabrata and C. krusei). A number of antifungal agents are approved for pediatric use, and their limits and advantages are analyzed in this article, but only micafungin is authorized for use in neonatal patients. Further trials are required in order to assess whether additional drugs could have a similar indication for neonatal use. A big issue is the correct identification of the most effective dosing regimen, because the drug pharmacokinetics is peculiar and somewhat unpredictable in newborn patients. In addition to fluconazole prophylaxis, other measures could be taken to prevent fungal infections in at-risk neonates, such as increasing hygienic measures, encouraging breast-feeding, removing CVCs, using probiotics, and decreasing or avoiding the use of drugs promoting the development of systemic mycoses.
References
Borghesi A, Stronati M. Strategies for the prevention of hospital-acquired infections in the neonatal intensive care unit. J Hosp Infect 2008; 68: 293-300; http://dx.doi.org/10.1016/j.jhin.2008.01.011
Karlowicz MG, Hashimoto LN, Kelly RE Jr, et al. Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics 2000; 106: E63; http://dx.doi.org/10.1542/peds.106.5.e63
Rowen JL, Tate JM. Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr Infect Dis J 1998; 17: 1007-11; http://dx.doi.org/10.1097/00006454-199811000-00008
Wade KC, Wu D, Kaufman DA, et al; National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008; 52: 4043-9; http://dx.doi.org/10.1128/AAC.00569-08
Watt K, Benjamin DK Jr, Cohen-Wolkowiez M. Pharmacokinetics of antifungal agents in children. Early Hum Dev 2011; 87 Suppl 1: S61-S65; http://dx.doi.org/10.1016/j.earlhumdev.2011.01.014
Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006; 50: 935-42; http://dx.doi.org/10.1128/AAC.50.3.935-942.2006
Kotwani RN, Gokhale PC, Bodhe PV, et al. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates. Int J Pharm 2002; 238: 11-5; http://dx.doi.org/10.1016/S0378-5173(02)00066-2
Mehta P, Vinks A, Filipovich A, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006; 12: 235-40; http://dx.doi.org/10.1016/j.bbmt.2005.10.010
Groll AH, Stergiopoulou T, Roilides E, et al. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 2005; 14: 489-509; http://dx.doi.org/10.1517/13543784.14.4.489
Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. Med Vet Mycol 1997; 35: 79-86; http://dx.doi.org/10.1080/02681219780000961
Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501-17
Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-45; http://dx.doi.org/10.1128/AAC.49.11.4536-4545.2005
Sáez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009; 53: 869-75; http://dx.doi.org/10.1128/AAC.00868-08
Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009; 53: 1450-6; http://dx.doi.org/10.1128/AAC.01027-08
Castagnola E, Cappelli B, Faraci M, et al. Maintenance of therapeutic concentrations of caspofungin after temporary treatment interruption (48 hours) in a child with invasive aspergillosis. Antimicrob Agents Chemother 2007; 51: 3775; http://dx.doi.org/10.1128/AAC.00890-07
Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010; 87: 93-9; http://dx.doi.org/10.1038/clpt.2009.200
Mehta PA, Vinks AA, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010; 16: 1458-62; http://dx.doi.org/10.1016/j.bbmt.2010.05.002; http://dx.doi.org/10.1016/j.bbmt.2009.12.319
Tabata K, Katashima M, Kawamura A, et al. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull 2006; 29: 1706-11; http://dx.doi.org/10.1248/bpb.29.1706
Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54: 2633-7; http://dx.doi.org/10.1128/AAC.01679-09
Cohen NR, Tatituri RV, Rivera A, et al. Innate recognition of cell wall β-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe 2011; 10: 437-50; http://dx.doi.org/10.1016/j.chom.2011.09.011
Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50: 632-8; http://dx.doi.org/10.1128/AAC.50.2.632-638.2006
Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6; http://dx.doi.org/10.1128/JCM.01901-07; http://dx.doi.org/10.1128/JCM.01107-08
Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23: 1093-7
Mrówczyński W, Wojtalik M. Caspofungin for Candida endocarditis. Pediatr Infect Dis J 2004; 23: 376; http://dx.doi.org/10.1097/00006454-200404000-00029
Castagnola E, Franceschi A, Natalizia AR, et al. Combined antifungal therapy for persistent central venous catheter-related candidemia in extremely low birth weight neonates. J Chemother 2009; 21: 234-5
Manzoni P, Esposito S, Gallo E, et al. Switch therapy in full-term neonates with presumed or proven bacterial infection. J Chemother 2009; 21: 68-73
Natale F, Castronovo A, Regoli D, et al. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant. Pediatr Infect Dis J 2009; 28: 452; http://dx.doi.org/10.1097/INF.0b013e31819d1cf1
Mondello I, Rossi A, Serrao G, et al. Preterm neonates in NICU treated with Caspofungin: our experience. Early Hum Dev 2009; 85: S93-S98
Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med 2004; 5: 181-3; http://dx.doi.org/10.1097/01.PCC.0000113264.00053.AF
Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25: 770-7; http://dx.doi.org/10.1038/sj.jp.7211380
Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93; http://dx.doi.org/10.1086/520980
Queiroz-Telles F, Berezin E, Leverger G, et al; Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820-6; http://dx.doi.org/10.1097/INF.0b013e31817275e6
Cateau E, Berjeaud JM, Imbert C. Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. Int J Antimicrob Agents 2011; 37: 380-4; http://dx.doi.org/10.1016/j.ijantimicag.2010.12.016
Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008; 62: 153-5; http://dx.doi.org/10.1093/jac/dkn160
Manzoni P, Benjamin DK, Hope W, et al. The management of Candida infections in preterm neonates and the role of micafungin. J Matern Fetal Neonatal Med 2011; 24: 24-7; http://dx.doi.org/10.3109/14767058.2011.604929
Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25: 1110-5; http://dx.doi.org/10.1097/01.inf.0000245103.07614.e1
Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009; 28: 412-5; http://dx.doi.org/10.1097/INF.0b013e3181910e2d
Wynn JL, Tan S, Gantz MG, et al. Outcomes following candiduria in extremely low birth weight infants. Clin Infect Dis 2012; 54: 331-9; http://dx.doi.org/10.1093/cid/cir800
Manzoni P, Mostert M, Leonessa ML, et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42: 1735-42; http://dx.doi.org/10.1086/504324
Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 2011; 31: 63-9; http://dx.doi.org/10.1038/jp.2010.57
Manzoni P, Rinaldi M, Cattani S, et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009; 302: 1421-8; http://dx.doi.org/10.1001/jama.2009.1403
Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345: 1660-6; http://dx.doi.org/10.1056/NEJMoa010494
Manzoni P, Stolfi I, Pugni L, et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections; Italian Society of Neonatology. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007; 356: 2483-95; http://dx.doi.org/10.1056/NEJMoa065733
Kaufman DA, Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants. Clin Perinatol 2010; 37: 611-28; http://dx.doi.org/10.1016/j.clp.2010.06.003
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
